Slingshot members are tracking this event:

Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AGN Community voting in process

Additional Information

Additional Relevant Details - Potential Treatment for Patients with Facial Erythema (Redness) Associated with Rosacea -
- Allergan Expects PDUFA Date in First Half 2017 -

Allergan announced that the New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults, has been accepted by the U.S. Food and Drug Administration (FDA) for standard review. Allergan expects the Prescription Drug User Fee Act (PDUFA) date to be in the first half of 2017.
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 24, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Oxymetazoline Hci Cream